Condition: DLL3-expressing Tumors · PET / CT · Neuroendocrine Cancer · Sponsor: The First Affiliated Hospital of Xiamen University
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.
This description comes directly from the study's public registry record.
Liang Zhao · 86 18818350620 · wzhaoliang01@163.com
Haojun Chen · 86 18659285282 · leochen0821@foxmail.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07458906